You are here

Article Text

Article menu

Download PDFPDF

Section 5: Patient safety and quality assurance
5PSQ-070 Pharmaceutical care in an onco-haematological clinical trials unit
Free
  1. L García Basas1,
  2. C Varon-Galcera2,
  3. P Garcia Ortega2,
  4. E Serramontmany Morante1,
  5. S Gimenez Giner1,
  6. M Carreres Prieto1,
  7. P Rovira Torres1,
  8. I Cidoncha Muñoz1,
  9. MQ Gorgas Torner3
  1. 1Hospital Universitario Vall D’hebron, Pharmacy – Vall D’hebron Instituto de Oncología Vhio, Barcelona, Spain
  2. 2Hospital Universitario Vall D`Hebron, Pharmacy – Vall D’hebron Instituto de Oncología Vhio, Barcelona, Spain
  3. 3Hospital Universitario Vall D’hebron, Pharmacy, Barcelona, Spain

Abstract

Background and Importance The pharmacist’s role in the health care for patients participating in clinical trials (CTs) goes beyond telling them how to take the medication at the start of treatment. CT protocols are very complex and compliance with all their requirements is essential.

Patients always have available a pharmacy direct phone and email in order to make it easier to solve any queries they may have about drug-drug interactions, side effects or dietary and daily living recommendations.

Aim and Objectives To evaluate all pharmaceutical care queries addressed to the pharmacist team in a CTs unit.

Material and Methods Retrospective study carried out in a tertiary university hospital over a 7-months period (January – July 2022). All the consultations were evaluated and classified according to the phase of the CT in which the patient was included, sex, pathology, person who asked (patient, oncologist, etc.), communication media and reason of consulting.

Results A total of 596 queries were received, mostly about patients included in phase I trials (58,6%). The number of consultations increased steadily from January (37) to July (115).

According to sex and pathology, 559 queries could be evaluated. More than half were about women (58,9%). Most frequent consultations were about patients with breast (17,4%), lung (14,1%) and genitourinary (13,8%) cancer.

Of the fully evaluable queries (494), 40,7% were done by patients, followed by study coordinators (32,8%) and physicians (25,9%). Most of the consultations (57,7%) were received by email. Related to the topic, almost all of the queries were related to interactions with concomitant therapies (92,5%), followed by instructions on how to take the drug (3.8%).

Conclusion and Relevance Pharmacists receive a huge number of consultations about drug-drug interactions. Both patients and healthcare professionals need to have a quick way to have their consultations solved.

Continuous pharmaceutical attention is vital to ensure the efficacy, safety and controlled use of the investigational drug and to facilitate compliance with CT protocols.

Conflict of Interest No conflict of interest

http://dx.doi.org/10.1136/ejhpharm-2023-eahp.284

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.